Other MLL1 inhibitors including MI-136 and MI-503 share a thienopyrimidine scaffolding and function via abrogation of the MLL1/Menin association to induce cell death in models of MLL1-translocated leukemias and androgen receptor–dependent prostate cancer (14, 26). The gene discussed is KMT2A; the disease is prostate carcinoma.